- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 189352, 7 pages
Extremely Low-Frequency Magnetic Field Enhances the Therapeutic Efficacy of Low-Dose Cisplatin in the Treatment of Ehrlich Carcinoma
Biophysics Department, Faculty of Science, Cairo University, Al Gammaa Street, Giza 12613, Egypt
Received 8 November 2012; Revised 25 December 2012; Accepted 26 December 2012
Academic Editor: Kazim Husain
Copyright © 2013 Nihal S. El-Bialy and Monira M. Rageh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. Gottfried, R. Ramlau, M. Krzakowski et al., “Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results,” Journal of Thoracic Oncology, vol. 3, no. 2, pp. 152–157, 2008.
- G. Türk, A. Ateşşahin, M. Sönmez, A. O. Çeribaşi, and A. Yüce, “Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid,” Fertility and Sterility, vol. 89, no. 5, pp. 1474–1481, 2008.
- Z. Suo, S. J. Lippard, and K. A. Johnson, “Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization,” Biochemistry, vol. 38, no. 2, pp. 715–726, 1999.
- I. Arany and R. L. Safirstein, “Cisplatin nephrotoxicity molecular mechanisms,” Cancer Therapy, vol. 1, pp. 47–61, 2003.
- S. W. Thompson, L. E. Davis, M. Kornfeld, R. D. Hilgers, and J. Standefer, “Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies,” Cancer, vol. 54, no. 7, pp. 1269–1275, 1984.
- F. P. T. Hamers, W. H. Gispen, and J. P. Neijt, “Neurotoxic side-effects of cisplatin,” European Journal of Cancer, vol. 27, no. 3, pp. 372–376, 1991.
- H. Masuda, T. Tanaka, and U. Takahama, “Cisplatin generates superoxide anion by interaction with DNA in a cell-free system,” Biochemical and Biophysical Research Communications, vol. 203, no. 2, pp. 1175–1180, 1994.
- K. Wozniak, A. Czechowska, and J. Blasiak, “Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor ST1571,” Chemico-Biological Interactions, vol. 147, no. 3, pp. 309–318, 2004.
- L. M. G. Antunes, J. D. C. Darin, and M. D. L. P. Bianchi, “Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study,” Pharmacological Research, vol. 41, no. 4, pp. 405–411, 2000.
- N. I. Weijl, T. J. Elsendoorn, E. G. Lentjes, et al., “Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in ancer patients treated with cisplatin-based chemotherapy: a randomized, double-blind, placebo-controlled study,” European Journal of Cancer, vol. 40, no. 11, pp. 1713–1723, 2004.
- S. Tofani, “Physics may help chemistry to improve medicine: a possible mechanism for anticancer activity of static and ELF magnetic fields,” Physica Medica, vol. 15, no. 4, pp. 291–294, 1999.
- S. Tofani, D. Barone, M. Cintorino, et al., “Tumor growth inhibition, apoptosis and loss of P53expession induced in vivo and in vitro by magnetic fields,” Proceedings of the American Association for Cancer Research, vol. 40, p. 488, 1999.
- S. Tofani, D. Barone, M. Cintorino et al., “Static and ELF magnetic fields induce tumor growth inhibition and apoptosis,” Bioelectromagnetics, vol. 22, no. 6, pp. 419–428, 2001.
- S. Tofani, M. Cintorino, D. Barone et al., “Increased mouse survival, tumor growth inhibition and decreased immunoreactive P53 after exposure to magnetic fields,” Bioelectromagnetics, vol. 23, no. 3, pp. 230–238, 2002.
- S. Tofani, D. Barone, S. Peano, P. Ossola, F. Ronchetto, and M. Cintorino, “Anticancer activity by magnetic fields: inhibition of metastatic spread and growth in a breast cancer model,” IEEE Transactions on Plasma Science, vol. 30, no. 4, pp. 1552–1557, 2002.
- National Research Council, Guide For the Care and Use of Laboratory Animals, National Academy Press, Washington, DC, USA, 1996.
- W. M. Awara, S. H. El-Nabi, and M. El-Gohary, “Assessment of vinyl chloride-induced DNA damage in lymphocytes of plastic industry workers using a single-cell gel electrophoresis technique,” Toxicology, vol. 128, no. 1, pp. 9–16, 1998.
- P. Moller, L. E. Knudsen, S. Loft, and H. Wallin, “The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 10, pp. 1005–1015, 2000.
- N. P. Singh, M. T. McCoy, R. R. Tice, and E. L. Schneider, “A simple technique for quantitation of low levels of DNA damage in individual cells,” Experimental Cell Research, vol. 175, no. 1, pp. 184–191, 1988.
- R. R. Tice, E. Agurell, D. Anderson, et al., “Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing,” Environmental and Molecular Mutagenesis, vol. 35, no. 3, pp. 206–221, 2000.
- W. Schmidt, “The micronucleus test for cytogenetic analysis,” in Chemical Mutagens, Principles and Methods For Their Detection, A. Hollaender, Ed., pp. 31–53, Plenum Press, New York, NY, USA, 1976.
- D. K. Agarwal and L. K. S. Chauhan, “An improved chemical substitute for fetal calf serum for the micronucleus test,” Biotechnic and Histochemistry, vol. 68, no. 4, pp. 187–188, 1993.
- I. D. Adler, “Cytogenetic tests in mammals,” in Mutagenicity Testing, A Practical Approach, S. Venitt and J. M. Parry, Eds., pp. 275–306, IRL Press, Oxoford, UK, 1984.
- S. C. Sweetman, Antineoplastic and Immunosuppressant. The Complete Drug Reference, Pharmaceutical Press, London, UK, 33rd edition, 2002.
- A. Zicca, S. Cafaggi, M. A. Mariggio et al., “Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats,” European Journal of Pharmacology, vol. 442, no. 3, pp. 265–272, 2002.
- E. C. Friedberg, G. C. Walker, and W. Siede, “Cross-linking agents,” in DNA, Repair and Mutagenesis, pp. 33–42, ASM Press, Washington, DC, USA, 1995.
- R. C. Choudhury and M. B. Jagdale, “Vitamin E protection from/potentiation of the cytogenetic toxicity of cisplatin in swiss mice,” Journal of Chemotherapy, vol. 14, no. 4, pp. 397–405, 2002.
- M. Yoshida, A. Fakuda, M. Hara, A. Terada, Y. Kitanaka, and S. Owada, “Melatonin prevents the increase in hydroxyl radical-spin trap adduct formation caused by the addition of cisplatin in vitro,” Life Sciences, vol. 72, no. 15, pp. 1773–1780, 2003.
- R. Zhang, Y. Niu, and Y. Zhou, “Increased the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XXRCCI abrogation related mechanisms,” Toxicology Letters, vol. 192, no. 2, pp. 108–114, 2010.
- B. S. De Martinis and M. D. L. P. Bianchi, “Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats,” Pharmacological Research, vol. 44, no. 4, pp. 317–320, 2001.
- B. J. Chang, M. Nishikawa, E. Sato, K. Utsumi, and M. Inoue, “L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine,” Archives of Biochemistry and Biophysics, vol. 405, no. 1, pp. 55–64, 2002.
- M. Satoh, N. Kashihara, S. Fujimoto et al., “A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 1183–1190, 2003.
- J. S. Kim, L. He, and J. J. Lemasters, “Mitochondrial permeability transition: a common pathway to necrosis and apoptosis,” Biochemical and Biophysical Research Communications, vol. 304, no. 3, pp. 463–470, 2003.
- G. Kroemer and J. C. Reed, “Mitochondrial control of cell death,” Nature Medicine, vol. 6, no. 5, pp. 513–519, 2000.
- S. Tofani, D. Barone, M. Berardelli et al., “Static and ELF magnetic fields enhance the in vivo anti-tumor efficacy of cis-platin against lewis lung carcinoma, but not of cyclophosphamide against B16 melanotic melanoma,” Pharmacological Research, vol. 48, no. 1, pp. 83–90, 2003.
- P. Thomas, N. Holland, C. Bolognesi et al., “Buccal micronucleus cytome assay,” Nature Protocols, vol. 4, no. 6, pp. 825–837, 2009.
- Y. Miyakoshi, H. Yoshioka, Y. Toyama, Y. Suzuki, and H. Shimizu, “The frequencies of micronuclei induced by cisplatin in newborn rat astrocytes are increased by 50-Hz, 7.5- and 10-mT electromagnetic fields,” Environmental Health and Preventive Medicine, vol. 10, no. 3, pp. 138–143, 2005.